Navigation Links
Independent Data Monitoring Committee Recommends Resuming Enrollment of Non-Squamous NSCLC Patients in the Motesanib MONET1 Trial
Date:2/11/2009

THOUSAND OAKS, Calif. and CAMBRIDGE, Mass., Feb. 11 and OSAKA, Japan (Feb. 12, 2009) /PRNewswire-FirstCall/ -- Amgen (Nasdaq: AMGN), Millennium: The Takeda Oncology Company, and its parent company Takeda Pharmaceutical Company Limited (TSE:4052) today announced the Independent Data Monitoring Committee (DMC) for the MONET1 trial has recommended the trial resume enrollment of patients with non-squamous non-small cell lung cancer (NSCLC) following a three-month enrollment suspension. MONET1 is a Phase 3 study evaluating motesanib (AMG 706) in combination with paclitaxel and carboplatin for the first-line treatment of advanced NSCLC. Motesanib is part of a co-development program between Amgen, Millennium and Takeda.

The recent DMC guidance recommends the trial be re-opened only to patients with non-squamous cell histology. Non-squamous cell NSCLC is a histological subtype of NSCLC representing approximately two-thirds of the study population. Amgen, Millennium and Takeda plan to follow this recommendation which will require modifications to the study design of MONET1. Enrollment will resume once these changes are sanctioned by appropriate global health authorities.

In November 2008 the DMC recommended treatment discontinuation in subjects with squamous histology, and enrollment suspension in subjects with non-squamous histology. This recommendation was based on an observation of higher early mortality rates in the motesanib group compared to the placebo group and a higher incidence of hemoptysis in the squamous population. Patients with non-squamous NSCLC receiving motesanib were allowed to continue treatment during the temporary suspension.

"We endorse the DMC's decision to include only patients with non-squamous cell tumors in MONET1," said Roger M. Perlmutter, M.D., Ph.D., executive vice presid
'/>"/>

SOURCE Amgen
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Mindset Media Study Reveals Which Independent Voters Favor Obama Vs. McCain
2. Independent Analyses of the SEAS, SHARP and IMPROVE-IT Studies of Ezetimibe
3. Modigene Platform Validated in Independent Phase III Trial of CTP Technology
4. Emisphere Announces Data From Independent Clinical Study of Effects of Oral GLP-1 on Glucose and Insulin Concentrations
5. New Study Shows BENICAR(R) (olmesartan medoxomil) Reverses Blood Vessel Damage Independent of Blood Pressure Lowering
6. Soliris(R) Improved Fatigue Independent of Changes in Anemia in Patients with PNH by Controlling Hemolysis
7. Two Large, Independent Outcomes Trials Offer New Important Safety Information on Cardiovascular Effects of AVANDIA(R)
8. ASPIRE Independent Review Board Announces 10 Ways to Protect Participants Rights in Clinical Drug Trials and Optimize Results From Research
9. Promise of Vicals CMV Vaccine Noted by Independent Experts
10. Video: Major Independent Trial Demonstrates Significant Anticancer Benefit of Zometa(R) in Women With Early-Stage Breast Cancer
11. Seven Presentations by Two Independent Research Groups Highlight Advantages of Pressure Cycling Technology (PCT) at Scientific Symposia in Philadelphia, Boston, and New York City
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2015)... 2015 RnRMarketResearch.com adds Syringes ... report that provides an overview of syringes and ... from in-house databases, secondary and primary research. ... products pipeline spread across 124 pages, talking about ... and 5 figures is now available at ...
(Date:7/31/2015)... -- According to a new market research report ... Ethylene Oxide, Filtration, E-beam, Gamma), Services (Onsite & Offsite), Consumables ... Forecast to 2020", published by MarketsandMarkets, The Sterilization Equipment Market ... at a CAGR of 7.6%.from 2015 to 2020. ... ables and 37 F ...
(Date:7/31/2015)... 2015 Egalet Corporation (Nasdaq: EGLT ... focused on developing, manufacturing and marketing innovative pain ... announced underwritten public offering of 7,666,667 shares of ... of $11.25 per share. The shares of common ... upon the exercise in full by the underwriters ...
Breaking Medicine Technology:Syringes and Needles Market Products Pipeline Review 2015 Report 2Syringes and Needles Market Products Pipeline Review 2015 Report 3Syringes and Needles Market Products Pipeline Review 2015 Report 4Syringes and Needles Market Products Pipeline Review 2015 Report 5Sterilization Equipment Market is Expected to Reach USD 6.1 Billion by 2020 2Sterilization Equipment Market is Expected to Reach USD 6.1 Billion by 2020 3Sterilization Equipment Market is Expected to Reach USD 6.1 Billion by 2020 4Egalet Announces Closing of Public Offering of Common Stock and Exercise in Full of Underwriters' Option to Purchase Additional Shares 2Egalet Announces Closing of Public Offering of Common Stock and Exercise in Full of Underwriters' Option to Purchase Additional Shares 3Egalet Announces Closing of Public Offering of Common Stock and Exercise in Full of Underwriters' Option to Purchase Additional Shares 4
... May 2, 2012 Janssen Research & Development, LLC, ... Drug Applications (sNDAs) to the U.S. Food and Drug ... ® (rivaroxaban), an oral anticoagulant, to treat patients ... and prevention of recurrent venous thromboembolism (VTE). ...
... Official journal of the American Association for ... of scientific, technical and medical information products and services, announces ... American Association for Geriatric Psychiatry (AAGP) to publish ... AJGP ) beginning in January 2013. "We are ...
Cached Medicine Technology:Janssen Research & Development Submits XARELTO® (rivaroxaban) to U.S. FDA for the Treatment and Prevention of Recurrent Venous Thromboembolism 2Janssen Research & Development Submits XARELTO® (rivaroxaban) to U.S. FDA for the Treatment and Prevention of Recurrent Venous Thromboembolism 3Janssen Research & Development Submits XARELTO® (rivaroxaban) to U.S. FDA for the Treatment and Prevention of Recurrent Venous Thromboembolism 4Janssen Research & Development Submits XARELTO® (rivaroxaban) to U.S. FDA for the Treatment and Prevention of Recurrent Venous Thromboembolism 5Janssen Research & Development Submits XARELTO® (rivaroxaban) to U.S. FDA for the Treatment and Prevention of Recurrent Venous Thromboembolism 6Janssen Research & Development Submits XARELTO® (rivaroxaban) to U.S. FDA for the Treatment and Prevention of Recurrent Venous Thromboembolism 7Janssen Research & Development Submits XARELTO® (rivaroxaban) to U.S. FDA for the Treatment and Prevention of Recurrent Venous Thromboembolism 8Elsevier Selected as New Publisher of The American Journal of Geriatric Psychiatry 2Elsevier Selected as New Publisher of The American Journal of Geriatric Psychiatry 3
(Date:8/1/2015)... ... ... Tina Wilcoxson, owner of Freeport Maine’s Royal River Natural Foods, was named ... Retail Federation, the largest retail trade association in the world, for her “advocacy and ... be named as such. According to the NRF’s website, Retail Champions are “Main Street ...
(Date:8/1/2015)... ... August 01, 2015 , ... Lume Wellness creators Alex, Robert, and Sam ... on the Apple AppStore. , The app is designed to track various metrics ... a tool to view personal health and use this information for positive behavior modification. ...
(Date:7/31/2015)... ... July 31, 2015 , ... That’s right, the STASH ... STASH awards? The Significant Technological Achievements in Secretive Horticulture (or STASH) Awards, featured ... tried-and-true products that have stood the test of time. These include lighting products, ...
(Date:7/31/2015)... ... August 01, 2015 , ... Super Bowl 50 will emanate from Levi’s ... biggest day each year is the Super Bowl. In the two weeks that separate the ... the host venue. The 2016 Super Bowl game will mark the 50th time it has ...
(Date:7/31/2015)... ... July 31, 2015 , ... Last week, ... GoodThreads. The store can be accessed by visiting http://www.curemeso.org/store . , “Our ... customizable. The best part: whenever a product is purchased, the Meso Foundation receives ...
Breaking Medicine News(10 mins):Health News:Local Retail Advocate Wins National Recognition 2Health News:Lume Wellness Launches Health and Fitness Tracker iPhone App 2Health News:The High Times S.T.A.S.H. Awards Are in, Guess Who Took Home the Prize for “Best Grow System” 2Health News:Cheap 2016 Super Bowl Tickets at Levi's Stadium: Ticket Down Slashes Ticket Prices on Super Bowl 50 Tickets in Santa Clara, CA at Levi's Stadium 2Health News:Mesothelioma Organization Launches New Store 2Health News:Mesothelioma Organization Launches New Store 3
... Acute non-variceal gastrointestinal bleeding accounts for approximately 20% ... Although endoscopy has been used as a first-line ... intervention can be used as a safe diagnostic ... that is refractory to endoscopic treatment. The incidence ...
... type of cellular adaptor protein and transcriptional co-activator. In ... overexpressed and highly activated in hepatic cancers and mammary ... of the inhibitor of apoptotic protein (IAP) family, which ... cell protease receptor-1 in the human genomic library in ...
... , MENLO PARK, Calif., Sept. 16 ... the development of biotherapeutic and pharmaceutical products, announced today that ... Kit for rapid detection of anti-drug antibodies (ADA) for use ... life science researchers with new levels of throughput, speed and ...
... , ST. PETERSBURG, Fla., Sep. 16 ... announced today the launch of eMed-Trac, a live instant tracking ... impairments, or children who need to be closely supervised by ... , The eMed-Trac device operates through global ...
... , , BRAINTREE, Mass. and ... HAE ) announced today that it has signed a ... a cooperative of community blood centers. The contract provides ... of innovative blood management software products, including Prelude and Interlude, ...
... trigger the neurodegenerative disease, study finds , TUESDAY, Sept. ... in regular contact with pesticides may be at increased ... Researchers asked 519 Parkinson,s patients and 511 people without ... toxins, including pesticides and solvents. Working in agriculture, education, ...
Cached Medicine News:Health News:ForteBio Launches Dip and Read(TM) Immunogenicity Assay Kit for Rapid Detection of Anti-Drug Antibodies 2Health News:World's First Emergency Medical Information Franchise Launches GPS Tracking Device 2Health News:World's First Emergency Medical Information Franchise Launches GPS Tracking Device 3Health News:World's First Emergency Medical Information Franchise Launches GPS Tracking Device 4Health News:Haemonetics Signs Comprehensive Agreement with Blood Centers of America 2Health News:Pesticides Linked to Parkinson's 2
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: